Ophthalmology Consultants, Ltd — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$21,295	14
2024	Research	$72,125	14
2023	Research	$43,205	11
2022	Research	$90,185	13
2021	Research	$14,690	12
2020	Research	$32,435	10
2019	Research	$93,722	17

Breakdown

Who paid Research payments · program years 2019–2025

Glaukos Corporation $334,977 87 payments
Carl Zeiss Meditec Production LLC $32,680 4 payments

Studies the money was for Research payments · program years 2019–2025

Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $61,042 13 payments
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension $51,385 16 payments
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus $40,535 11 payments
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus $38,900 8 payments
A Multi-Center, Prospective Clinical Evalutation of the Safety and Effectiveness of the CT Lucia 611P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal. $32,680 4 payments
Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $32,435 10 payments
Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $14,690 12 payments
Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $2,805 2 payments
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone $1,500 1 payment
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream 4%, 6% and 8% BID for the Treatment of Signs and Symptoms of Dry Eye Disease $1,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.